Cellular and Humoral Immunity to SARS‐CoV‐2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease‐Modifying Therapies: A Multi‐Ethnic Observational Study

OBJECTIVE: The objective of this study was to determine the impact of multiple sclerosis (MS) disease‐modifying therapies (DMTs) on the development of cellular and humoral immunity to severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) infection. METHODS: Patients with MS aged 18 to 60 year...

Descripción completa

Detalles Bibliográficos
Autores principales: Kister, Ilya, Patskovsky, Yury, Curtin, Ryan, Pei, Jinglan, Perdomo, Katherine, Rimler, Zoe, Voloshyna, Iryna, Samanovic, Marie I., Cornelius, Amber R., Velmurugu, Yogambigai, Nyovanie, Samantha, Kim, Joseph J., Tardio, Ethan, Bacon, Tamar E., Zhovtis Ryerson, Lana, Raut, Pranil, Pedotti, Rosetta, Hawker, Kathleen, Raposo, Catarina, Priest, Jessica, Cabatingan, Mark, Winger, Ryan C., Mulligan, Mark J., Krogsgaard, Michelle, Silverman, Gregg J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082484/
https://www.ncbi.nlm.nih.gov/pubmed/35289960
http://dx.doi.org/10.1002/ana.26346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082484/
https://www.ncbi.nlm.nih.gov/pubmed/35289960
http://dx.doi.org/10.1002/ana.26346

Ejemplares similares